PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB)

Cancer drugs represent 40 per cent of all medicines in clinical trials

April 28, 2026

Review of the Bank Act postponed to 2033

November 6, 2025

High-cost medications weigh heavily on public drug plans

November 5, 2025

Canada among leading countries for new drug adoption

June 25, 2025

United States drug policy will mean increasing costs for private insurance plans

May 30, 2025

Prescription drug expenditures rebound following the COVID-19 pandemic

February 27, 2025

Insurers must manage drug cost inflation in 2025

January 21, 2025

Canadian medicine prices remain higher than all price board reference countries

December 11, 2024